A phase I/II trial of RAD 001 with gefitinib in patients with castrate metastatic prostate cancer and glioblastoma multiforme

David R. Shaffer,L. E. Abrey,K. W. Beekman,C. Eicher,M. Morris,Susan F. Slovin,J. Feldstein,Steven M. Larson,Neal Rosen,Howard I. Scher

A phase I/II trial of RAD 001 with gefitinib in patients with castrate metastatic prostate cancer and glioblastoma multiforme

2006

David R. Shaffer
L. E. Abrey
K. W. Beekman
C. Eicher
M. Morris
Susan F. Slovin
J. Feldstein
Steven M. Larson
Neal Rosen
Howard I. Scher

14520 Background: Inactivation of the Pten tumor suppressor gene, leading to constitutive activation of the PI3K/AKT/mTOR pathway, is correlated with resistance to EGFR-targeted therapies. This tri...

Keywords:

Glioblastoma
Prostate cancer
Cancer research
Gefitinib
Oncology
Internal medicine
Medicine
phase i ii
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations